New drug delivery system for treating lung diseases
Official title: Bispecific immunotherapeutic delivery system for lung diseases
Funded at Proteogenomics Research Instit/sys/ Med · NIH-11103179 · Data updated 2026-11-12
This study is testing a new way to deliver medicine directly to the lungs to help people with lung diseases like Acute Respiratory Distress Syndrome (ARDS), aiming to make treatments work better while causing fewer side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Proteogenomics Research Instit/sys/ Med NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project start | August 1, 2023 |
| Project end | May 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $924,314 |
| NIH project number | 5R01HL169760-03 |
| Project ID | NIH-11103179 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with Acute Respiratory Distress Syndrome or other severe lung conditions.
✕Less likely to help
Patients with mild respiratory issues or those not diagnosed with acute lung diseases may not benefit from this research.
What this research studies
This research focuses on developing a novel drug delivery system designed to improve the treatment of lung diseases, particularly Acute Respiratory Distress Syndrome (ARDS). The approach involves creating a bispecific immunotherapeutic that can effectively target and penetrate lung tissue, overcoming barriers that typically hinder drug delivery. By utilizing a method that enhances the transport of therapeutics directly into the lungs, the goal is to minimize exposure to other tissues and reduce potential side effects. Patients may benefit from a more effective treatment with fewer complications and lower costs.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for patients suffering from lung diseases.
How similar studies have gone: While the approach of targeted drug delivery is being explored in various contexts, this specific method for lung diseases is relatively novel and has not been extensively tested.
Where this research is happening
-
Proteogenomics Research Instit/sys/ Med
La Jolla, United States Active
Researchers
- Principal investigator: Schnitzer, Jan Eugeniusz — Proteogenomics Research Instit/sys/ Med
- Study coordinator: Schnitzer, Jan Eugeniusz
Related research
Other NIH-funded projects on the same topics.
-
Clinical readiness for rare lung diseases (RLDC)
A group at the University of Cincinnati is building a program to speed up care for people with rare lung diseases by tracking patients over time, improving tests and treatments, and sharing information with patients and clinicians.
-
Epithelial cells trigger fibroblast activation in lung fibrosis through CTHRC1-TGFb signaling
A clinician-scientist at Duke is studying how lung lining cells may turn normal fibroblasts into fibrosis-causing cells, aiming to uncover new targets for treatment of diseases like BO and IPF.
-
Molecular origins of chronic lung diseases in the human lung
Researchers are mapping the tiny cell neighborhoods in diseased lungs to find early clues that could protect or restore normal lung function.
-
How lung cells and their surroundings drive fibrosis in interstitial lung diseases
A study to understand how airway cells, surrounding tissue, and their environment contribute to progressive scarring in interstitial lung diseases.
-
Loss of Cilia Maintenance in Acquired and Genetic Lung Diseases
Researchers are studying why tiny hair-like structures in the lungs lose their maintenance and how this affects people with asthma, COPD, and related airway diseases.
-
CMKLR1-targeted imaging to map lung inflammation in ALI and fibrotic lung diseases
A study to test a new PET imaging tool that targets CMKLR1 to visualize lung inflammation and help predict and monitor disease progression in patients with acute lung injury and fibrotic lung diseases.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.